Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

340 - Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: Observational case series


20 Dec 2015


Poster presentation 2


Vinayak Maka


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


V.V. Maka

Author affiliations

  • Medical Oncology, MS Ramaiah Memorial Hospital, 560054 - Bangalore/IN


Abstract 340


Epidermal growth factor receptor inhibitors are associated with toxicities affecting the skin and adnexal structures which affect the majority of treated patients. Trichomegaly connotes thick, curly, rigid eyelashes. Aim of this study was to evaluate patients undergoing treatment with erlotinib for EGFR mutation positive NSCLC for any anti EGFR toxicities on eye lashes.


In this retrospective study conducted over a period of six years from February 2009 to January 2015 in Department of Medical Oncology in our institute, we observed 24 patients with mean age of 55 years undergoing treatment with erlotinib for EGFR mutation positive NSCLC patients for any anti EGFR toxicities on eye lashes. We evaluated the interval between introduction of the drug and onset of symptoms, treatment response, and the clinical pattern of evolution of this reaction retrospectively.


Four patients presented trichomegaly typically affecting the both eyelids, which appeared in average 15 weeks after starting the drug treatment. Patients developed significant lengthening, rigid, and curly overgrowth of their eyelashes. Trichomegaly of eyelashes did not obscure vision but one patient developed eyelid irritation, including plugging of the meibomian glands with infection. In most cases, patients were managed with eyelash trimming, although systemic antibiotics and artificial tears were used for coexisting cutaneous toxicities. Treatment with epidermal growth factor receptor inhibitor was maintained in most patients.


Oncologists should be cognizant of these potential sequelae, for which referral to an ophthalmologist or dermatologist may sometimes be helpful. Left untreated these dermatological side-effects could represent a threat to patient compliance

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings